The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer

British Journal of Cancer

Volumn 87, Issue 11, 2002, Pages 1294-1300

  Yousef, G M ^a,b   Scorilas, A ^c   Magklara, A ^a,b   Memari, N ^a,b   Ponzone, R ^d   Sismondi, P ^d   Biglia, N ^d   Abd Ellatif, M ^e   Diamandis, E P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d UNIVERSITY OF TURIN   (Italy)

^e MANSOURA UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Cancer genes; Kallikreins; KLK15; Predictive markers; Prognostic factors; Serine proteases; Steroid hormones; Tumour markers

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; KALLIKREIN; KALLIKREIN 15; KALLIKREIN 3; PROGESTERONE; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; STEROID HORMONE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 19Q; DNA SYNTHESIS; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; KALLIKREINS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037132364     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600590     Document Type: Article

References (40)

1. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R (1996) A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2: 624-636
2. ASCO (1998) 1997 Update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 16: 793-795
3. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148-1156
4. Birrell SN, Hall RE, Tilley WD (1998) Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3: 95-103
5. Black MH, Diamandis EP (2000) The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 59: 1-14
6. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377
7. Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK (1994) Prognostic factors: Rationale and methods of analysis and integration. Breast Cancer Res Treat 32: 105-112
8. Cox DR (1972) Regression models and life tables. R Stat Soc B 34: 187-202
9. Diamandis EP (1998) Prostate-specific antigen-its usefulness in clinical medicine. Trends Endocrinol Metab 9: 310-316
10. Diamandis EP, Yousef GM (2001) Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn 1: 182-190
11. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000) Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579-583
12. EORTC (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.. Eur J Cancer 16; 1513-1515
13. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
14. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V (1998) The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782-4786
15. Hamilton A, Piccart M (2000) The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2. Ann Oncol 11: 647-663
16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
17. Lea OA, Kvinnsland S, Thorsen T (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res 49: 7162-7167
18. Magklara A, Grass L, Diamandis EP (2000) Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 59: 263-270
19. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP (2001) The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7: 806-811
20. Norberg T, Jansson T, Sjogren S, Martensson C, Andreasson I, Fjallskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J (1996) Over-view on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. Acta Oncol 35: 96-102
21. Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49-61
22. Scorilas A, Diamandis EP, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, Lopez-Otin C (1999a) Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: An independent favorable prognostic factor in node-positive patients. Clin Cancer Res 5: 1778-1785
23. Scorilas A, Talieri M, Ardavanis A, Courtis N, Dimitriadis E, Yotis J, Tsiapalis CM, Trangas T (2000) Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. Cancer Res 60: 5427-5433
24. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M (1999b) Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 5: 815-821
25. Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel IIIVG, Somerfield MR (1999) American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17: 1080-1082
26. Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S (1992) Androgen receptors in operable breast cancer: Relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18: 112-118
27. Stearns V, Yamauchi H, Hayes DF (1998) Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 52: 239-259
28. Takayama TK, Carter CA, Deng T (2001) Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40: 1679-1687
29. Takayama TK, Fujikawa K, Davie EW (1997) Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272: 21582-21588
30. Tanimoto H, Underwood LJ, Shigemasa K, Yan Yan MS, Clarke J, Parmley TH, O'Brien TJ (1999) The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86: 2074-2082
31. Tormey DC, Lippman ME, Edwards BK, Cassidy JG (1983) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 98: 139-144
32. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ (1999) Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59: 4435-4439
33. Yousef GM, Chang A, Diamandis EP (2000a) Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 275: 11891-11898
34. Yousef GM, Diamandis EP (2001) The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 22: 184-204
35. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP (2001a) Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61: 3425-3431
36. Yousef GM, Magklara A, Diamandis EP (2000b) KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69: 331-341
37. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP (2001b) Molecular cloning of the human kallikrein 15 gene (KLK15). Up- regulation in prostate cancer. J Biol Chem 276: 53-61
38. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP (2000c) The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - Genomic characterization, mapping, tissue expression and hormonal regulation [In Process Citation]. Gene 254: 119-128
39. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P (1995) Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110
40. Zarghami N, Grass L, Diamandis EP (1997) Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75: 579-588